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Abstract 
The Total Thrombus-formation Analyser System (T-TAS) is a whole blood flow chamber 
system for the measurement of in vitro thrombus formation under variable shear stress 
conditions. Our current study sought to evaluate the potential utility of the T-TAS for the 
measurement of thrombus formation within human and mouse whole blood. T-TAS 
microchips (collagen, PL chip; collagen/tissue thromboplastin, AR chip) were used to analyse 
platelet or fibrin-rich thrombus formation respectively. Blood samples from humans (healthy 
and patients with mild bleeding disorders) and wild-type (WT), mice were tested. Light 
transmission lumi-aggregometer (lumi-LTA) was performed in PRP using several 
concentrations of ADP, adrenaline, arachidonic acid, collagen, PAR-1 peptide and 
ristocetin. Thrombus growth (N=22) increased with shear within PL (4:40±1.11, 3:25±0.43 
and 3:12±0.48 mins [1000, 1500 and 2000s-1]) and AR chips (3:55±0.42 and 1:49±0.19 
[240s-1 and 600s-1]). The area under the curve (AUC) on the PL chip was also reduced at 
1000s-1 compared to 1500/2000s-1 (260±51.7, 317± 55.4 and 301±66.2 respectively).  In 
contrast, no differences in the AUC between 240s-1 and 600s-1 were observed in the AR chip 
(1593±122 and 1591±158). The intra-assay coefficient of variation (CV) (n=10) in the PL 
chip (1000s-1) and AR chip (240s-1) were T1014.1%, T6016.7%, T10-6022.8% and AUC1024.4% 
or T10 9.03%, T808.64%, T10-8023.8% and AUC305.1%. AR chip thrombus formation was 
inhibited by rivaroxaban (1µM), but not with ticagrelor (10µM). In contrast, PL chip 
thrombus formation was totally inhibited by ticagrelor. T-TAS shows an overall agreement 
with lumi-LTA in 87% of patients (n=30) with normal platelet counts recruited into the 
genotyping and phenotyping of platelet (GAPP) study and suspected to have a platelet 
function defect. The onset (T10) of thrombus formation in WT mice (N= 4) was shorter when 
compared to humans e.g. PL chip (1000s-1) T10 were 02:02±00:23 and 03:30±0:45 
respectively). T-TAS measures in vitro thrombus formation and can be used for monitoring 
3 
 
antithrombotic therapy, investigating patients with suspected platelet function defects and 
monitoring platelet function within mice. 
Keywords 
Light transmission lumi-aggregometry, mild bleeding disorders, platelet aggregation, platelet 
function defects, total thrombus-formation system, WT mice 
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Introduction 
Haemostasis is an important process that maintains the integrity of the circulatory system and 
minimises blood loss upon vascular damage. When a blood vessel-wall is injured a number of 
concomitant events occur. Initially, circulating platelets are recruited to the site of injury, 
where they are activated to become a platelet plug. Simultaneously blood coagulation is 
triggered by tissue factor resulting in thrombin generation and fibrin formation. The 
formation of fibrin, together with the platelet plug become major components of the 
developing thrombus at the sight of injury to prevent bleeding [1].  
A number of instruments have now become available to investigate bleeding disorders by 
accessing platelet function defects. However, the most common used techniques such LTA 
are aggregation based and so do not access platelet in their physiological condition. The more 
recent developed methods such as the impact cone and plate(let) analyser (CPA), PFA-200 
and the Total Thrombus-formation Analysis System (T-TAS) are flow based methods using 
whole blood and therefore measure platelet function under more physiological conditions. 
Although both systems measure thrombus formation under high shear, CPA monitors platelet 
adhesion to a polystyrene plate and the PFA-200 measures thrombus formation within a small 
aperture [2]. Therefore, both are sensitive to VWF levels [3]. In contrast, the T-TAS has the 
advantage of evaluating thrombus formation in more physiological and variable flow 
conditions with varying effects of VWF levels [4].  
 
The T-TAS device is provided with two types of disposable ready-to-use microchips: (1) a 
platelet (PL) chip coated with collagen for assessing platelet thrombus formation and (2) an 
atherome (AR) chip coated with collagen and tissue factor for assessing white thrombus 
formation mediated by the activation of coagulation and platelets. The device therefore offers 
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a potential advantage of simultaneous assessment of both platelet and coagulation defects [5, 
6].  
 
The T-TAS was initially designed to monitor the effectiveness of antithrombotic agents. A 
number of studies have reported its potential utility in assessment of anti-platelet drugs e.g. 
aspirin, clopidogrel, PAR-1 and PAR-4 antagonists [6-8] and anti-thrombotic agents e.g. 
direct thrombin and factor Xa inhibitors [9]. T-TAS has also demonstrated high sensitivity in 
detecting coagulation disorders such as haemophilia [10] and von Willebrand disease [11], as 
well as platelet function defects for example, storage pool disease (SPD) [12]. In assessing 
acquired haemorrhagic conditions, the T-TAS was able to predict the risk of bleeding in atrial 
fibrillation patients undergoing catheter ablation [13]. Furthermore, T-TAS has been 
demonstrated to be a useful tool in the study of thrombus formation in blood taken from 
animal models such as miniature pigs [14] and mice [10, 15]. 
Materials and Methods 
Participants 
A total of 59 individuals (37 patients and 22 controls) were evaluated and recruited into the 
GAPP study (www.birmingham.ac.uk/plateletgapp) from 9 UK Haemophilia comprehensive 
care centres. All patients or their parents gave written informed consent in accordance with 
the GAPP project ethical approval (REC reference: 06/MRE07/36).    
Reagents  
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK). Arachidonic acid 
and U46619 were purchased from Cayman Chemical Company (Michigan, USA). The PAR-
1 peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, UK). Collagen was 
purchased from Takeda (Austria) and luciferin luciferase reagent (Chrono-lume) was 
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purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents were 
dissolved in phosphate-buffered saline (PBS) at pH 7.4 and stored as frozen aliquots, thawed 
and diluted in PBS when required and kept on ice. Collagen was stored as a concentrated 
stock at 1 mg/ml as supplied by the manufacturer at 4°C and diluted with the buffer provided. 
AR chip, PL chip, CaCl2 containing 1.25 mg/mL of Corn Trypsin Inhibitor (CaCTI) and 3.2% 
sodium citrate were provided by Quadratech Diagnostics Limited (Epsom, UK). 25 μg/ml 
hirudin blood tubes were purchased from Roche Diagnostics (Munich, Germany). Ticagrelor 
(10 mM) and Rivaroxaban (10 mM) stock solutions were provided by Leeds Institute of 
Cardiovascular and metabolic medicine, University of Leeds (Leeds, UK). 
Blood sampling, platelet preparation and platelet count 
Whole blood (40 ml) was obtained and anticoagulated with one tenth volume of 0.109 M/L 
buffered trisodium citrate in vacutainer plastic tubes (Becton Dickinson, Plymouth, UK). An 
additional (5 ml) blood was collected, 2 ml was anticoagulated with EDTA in vacutainer 
plastic tubes (Becton Dickinson, Plymouth, UK) and 3 ml was anticoagulated with hirudin in 
vacutainer plastic tubes (Roche Diagnostics, Munich, Germany), (final concentration, 25 
μg/ml).  The same volume of blood was collected from a healthy control at the same time in 
each Centre. Blood samples were immediately transported to the testing laboratory where 
they remained capped and stored upright at room and assayed within 4 hours (by T-TAS) and 
within 6 hours (by lumi-LTA) from collection. Platelet rich plasma (PRP) was prepared by 
centrifuging the citrated blood samples at 200 g for 20 min. Platelet-poor plasma (PPP) was 
prepared by further centrifugation at 1,000 g for 10 min. Both samples were transferred into 
15 ml Falcon tubes, capped and stored upright at room temperature. Whole blood platelet 
parameters were analysed from EDTA blood samples from patients and controls using the 
XN-1000 whole blood counter (Sysmex UK, Milton Keynes). An impedance analyser 
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(Coulter Z2 Beckman Coulter, High Wycombe, Bucks, UK) was used to count the platelets 
within the PRP by diluting 5 µl of PRP into 10 ml of fresh Isoton II diluent (Beckman 
Coulter, Bucks, UK).  
Platelet aggregation in platelet-rich plasma 
Tests were carried out as described previously [16].  Aggregation studies were performed by 
using a dual Chrono-log lumiaggregometer (model ChronoLog 460 VS aggregometer, 
LabMedics, UK) in 400 μL mini cuvettes and stirred at 1200 rpm at 37°C. The 100% line 
was set using autologous PPP and the 0% baseline established with native undiluted PRP.   
After one min platelets were stimulated with ADP (10, 30, and 100 µM), adrenaline (10, 30, 
and 100 µM), arachidonic acid (0.5, 1, and 1.5 mM), U46619 (1 and 3 µM), collagen (1 and 3 
µg/mL), collagen related peptide CRP (1, 3, and 10 µg/mL), PAR-1 peptide (10, 30 and 100 
µM), and ristocetin (1.5 and 2 mg/mL).  Platelet aggregation was monitored by measuring the 
change in optical density over 5 min after addition of the agonists and the maximal percent-
age of aggregation was recorded. ATP secretion from platelet dense granules was assessed 
simultaneously by lumi-LTA using the luciferase reagent (Chronolume) as described 
previously [16] 
Evaluation of thrombus formation under flow conditions on human blood 
In vitro thrombus formation was analysed on the T-TAS instrument (Zacros, Fujimori Kogyo 
Co. Ltd., Tokyo, Japan) using two types of microchips, the PL chip (width 40 μm × depth 40 
μm) (containing 25 capillary channels coated with type 1 collagen) and the AR chip (width 
300 µm, depth 60 or 120 µm, length 15 mm) (consisting of a single capillary channel coated 
with collagen and thromboplastin). The PL chip was used to analyse platelet thrombus 
formation (PTF) under three different shear rates (1000, 1500 and 2000s-1). Briefly, hirudin 
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anticoagulated whole blood (320 µL) was pipetted in the reservoir then perfused at 37°C 
through the PL chip by a pneumatic pump.  After the perfusion of blood was initiated, 
platelets were then activated by the collagen coated on the capillary. The AR chip was used to 
analyse white thrombus formation (WTF) under two different shear rates (240s-1 and 600s-1). 
Briefly, citrated whole blood (480 µl) was re-calcified by mixing with 20 µl of 0.3 M CaCTI 
immediately before it was pipetted in the reservoir. The re-calcified blood was then perfused 
at 37°C through the AR chip by the pneumatic pump.  After the perfusion of blood through 
the capillary was initiated, platelets and the extrinsic coagulation pathway were 
simultaneously activated by collagen and tissue thromboplastin. To prevent the outlet port 
from clotting, the blood is mixed with 25 mM EDTA (pH 10.5). The process of thrombus 
formation in both chips was monitored by flow pressure changes in the capillary using the 
pressure sensor located between the pump and the reservoir. As thrombus formation 
proceeded on the coated surface, the capillary is gradually occluded, increasing the flow 
pressure. Based on the flow pressure pattern, the following four parameters are used to 
analyse the results (i) T10 (time to reach 10 kPa) was defined as the onset of thrombus 
formation and represents the duration (min) for the flow pressure to increase to 10 kPa from 
baseline due to partial occlusion of microcapillaries. (ii) OT (occlusion time) was defined as 
the complete occlusion of the capillary, which coincides with a pressure of 60 and 80 kPa for 
the PL and AR chips respectively. (iii) T10–60 for PL chip and T10–80 for AR chip were 
defined as the interval between T10 and OT, representing the rate of thrombus growth; (iv) 
AUC (area under curve) is an area under the flow pressure curve (under 60/80 kPa) for 10/30 
min after the start of assay for the PL and AR chips respectively. AUC is used to quantify a 
decrease in WTF when OT is not achieved during the time period of assay. 
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Antithrombotic effects of ticagrelor and rivaroxaban under flow conditions 
Ticagrelor (final concentration, 10 µM) was incubated either in hirudin or citrate 
anticoagulated blood for 10 min at room temperature. Rivaroxaban (final concentration, 1 
µM) was incubated in citrate anticoagulated blood for 3-5 min at room temperature. After 
incubation blood were perfused through either the PL chip and/or AR chip within the T-TAS 
instrument as described above.   
Statistical analysis  
All control results were run on Graph Pad Prism version 7.0 software to demonstrate the 
normal distribution and to obtain the median and standard deviation values which were then 
used to determine the cut-off values.  Abnormal results by lumi-LTA were determined based 
on our previously published methodology that is based upon both the magnitude and time 
course of response [16, 17]. The time course, including reversibility is of particular 
importance. In contrast, abnormal thrombus formation by T-TAS was determined based on 
the cut off values of AUC10 and the T10 parameters calculated as the 5th percentile from 
healthy controls.  
Results 
Measurement of T-TAS in healthy subjects 
22 healthy subjects (10 males and 12 females; median age 31 ± 7 years) were investigated. 
Overall, the T-TAS shows some variation in thrombus formation among healthy subjects on 
both (PL and AR) chips (Figure 1A and 1C). Within the PL chip (Figure 1B), the onset (T10) 
value (median) and occlusion time (T60) at a shear rate of 1000 s-1 were greater than at 
1500/2000 s-1 (T10= 03:30, 03:02, 03:29 and T60= 08:10, 06:27, 06:42 respectively). In 
contrast, the AUC10 value (median) was reduced at a shear rate of 1000 s-1 than at 1500/2000 
s-1 (260, 317 and 301 respectively). Furthermore, the thrombus growth rates (T10-60) in the PL 
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chip (median) decreased as the shear rate increased (04:40, 03:25 and 03:12 respectively) 
(Figure 1B). A shear dependent decrease was also observed on the occlusion times (T80) and 
thrombus growth rates (T10-80) on the AR chip (T80=12:1 and 11:30; T10-80= 4:36 and 2:21 
respectively) (Figure 1D). However, no significant different of the AUC30 values (median) 
was observed between low and high shear values (1593 and 1591 respectively).  Surprisingly, 
the onset (T10) value (median) on AR chip was greater at high shear (09:19) than at the low 
shear (08:16) (figure 1D). 
Intra-assay coefficients of variation (CV) were calculated from 10 sequential measurements 
of a single sample obtained from one healthy subject (Table 1). Overall, the difference of CV 
between shear rates within the PL chip was more significant compared to the AR chip. On PL 
chip the CVs of T60, T10-60 and AUC10 were smaller at 2000 s− 1 than at 1000/1500 s− 1 whereas 
the CVs of T10 were almost identical at all three shear rates. In AR chip however, the CV of 
all four parameters were low at 600 s− 1 than that at 240 s− 1 (Table 1). 
Measurement of blood from healthy subjects spiked with antithrombotic drugs 
No thrombus formation was observed in the PL chip when blood was pre-treated with 
ticagrelor (10 µM) (Figure 1E). In contrast, thrombus formation in the AR chip was not 
affected by addition of ticagrelor (Figure 1F). However, thrombus formation in the PL chip 
was observed with blood pre-treated with rivaroxaban (1µM) but varies between subjects 
when perfused through the AR chip at lower shear rates (Figure 1G).  
Measurement of T-TAS on samples from patients recruited into the GAPP study with 
suspected platelet function defects. 
We analysed 30 patients (8 male and 22 female) with a median age 35 (range 7-73) recruited 
into the GAPP study and compared T-TAS (PL chip) results with lumi-LTA. All patients had 
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normal platelet counts (261 ± 68 x109/L). Of 30 patients tested (Figure 2C), 10 (33.3%) 
patients gave abnormal responses by lumi-LTA to one or more agonists as defined using 
previous criteria [17]. In contrast, 8 (27%) patients were detected to have abnormal thrombus 
formation by T-TAS, as defined using the cut off values obtained from healthy controls. T-
TAS detected an abnormality in 1 patient that was normal by lumi-LTA, whereas 3 samples 
were normal by T-TAS but abnormal by lumi-LTA (Figure 2A and 2B, respectively). The 
overall agreement between the two instruments is shown in table 2. 26/30 samples gave 
identical results by both tests, with the majority (19) giving normal responses, whereas 7 
samples gave abnormal results by both tests. In contrast, there was disagreement in 4/30 
samples. In this study we used AUC10 and the T10 parameters to identify a defect on T-TAS. 
7/8 (88%) samples with an abnormality detected by T-TAS have low values of AUC10. One 
patient however, had normal AUC10 value (AUC10=177.8s) but a delayed T10 parameter (T10 = 
5.44s).  
Analysis and identification of patients with platelet function defects 
Functional defects identified by lumi-LTA were classified into 4 main groups (Gi defects, 
secretion defects, COX-like defect and multiple defects) according to their pattern of 
responses to specific agonists as previously described [17]. As shown in figure 2D, T-TAS 
detected all patients classified by lumi-LTA with COX-like defect or secretion defects (1 and 
2 patients respectively).  In contrast, T-TAS only detected 1/3 patients with Gi defects but 3 
out of 4 with multiple defects.  
Measurement of T-TAS in sample from GAPP patients with thrombocytopenia 
recruited with suspected platelet function defects  
We additionally analysed 7 patients (2 male and 5 female) found to have mild to marked 
thrombocytopenia as characterized by low whole blood platelet counts (<150 x109/L), but 
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normal platelet counts in PRP when tested by lumi-LTA. The whole blood platelet counts 
(mean ± SD) were 77 ± 34 (x109/L). The waveform of each individual patient is presented in 
figure 2A. AUC10 parameters (Figure 2B) showed significant differences between healthy 
controls (n=22) and patients (n=7). All 7 patients tested exhibited abnormal thrombus 
formation within the T-TAS (Figure 2A). Interestingly, 4/7 patients were also detected by 
lumi-LTA to have platelet function defects (3 secretion and 1 Cox-like defects) in additional 
to their thrombocytopenia.  
Measurement of T-TAS in samples from WT mice  
Blood samples from WT (n=5) were tested using PL chips (1000 s-1 and 2000 s-1) and AR 
chips (240 s-1). Within the PL chip, shear enhanced thrombus formation was observed with 
all parameters; however, any differences in measurements between shear rates was only 
significant with the AUC10 parameter. For example, the values (median) at 1000 s-1 (T10 = 
02:02, T60 = 04:40 and T10-60 =02:38) were greater than at 2000 s-1 (T10 = 01:16, T60 = 03:26 
and T10-60 = 02:09). Consequently, the AUC10 at 1000 s-1 was shorter than at 2000 s-1 (405.5 
and 463.6 respectively) (Table 3). The values (median) of thrombus formation within the AR 
chip (240s-1) are shown in table 3. For example, the median values of T10, T80, T10-80 and 
AUC30 were 02:52, 06:41, 03:48 and 2048.98 respectively.     
The difference in thrombus formation between WT mice (n=5) and healthy humans (n=22) 
was then compared. Overall, thrombus formation in WT mice was more rapid on both the PL 
and AR chips (Figure 3A) than in humans. With PL chip measurements, the differences 
between two models were significant with all parameters. For example, WT mice values 
(median) at 1000 s-1 were T10 = 02:02, T60 = 04:40, T10-60 = 02:38 and AUC10 = 405.5 (table 3) 
whereas the values in humans (median) at the same shear were T10= 03:30, T60= 08:10, T10-60 
= 04:40 and AUC10 = 260 (results not shown). In contrast, with AR chip measurements the 
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different between two models were only significant with T10, T80 and AUC30 but not with T10-
80 (Figure 3C).  
Discussion 
The T-TAS is a flow chamber system that evaluates thrombus formation using whole blood 
samples that flow on different thrombogenic surfaces under arterial or venous shear 
conditions. This approach offers an advantage for rapidly assessing thrombus formation in 
more physiological conditions using whole blood under flow. Furthermore, this method 
requires comparatively small blood volumes (350 μl) making it potentially practical for 
clinical application [4]. Importantly, T-TAS has all the five requirements of flow assays 
methods as described by Roest et al. [18]. We therefore sought to evaluate the potential 
utility of the T-TAS for assessing thrombus formation in blood from healthy individuals, 
blood spiked with antithrombotic agents, blood from GAPP study patients with mild bleeding 
disorders and blood from mice. 
In healthy controls, both the start and end points of thrombus formation varied among 
individuals within both chips suggesting that measurements obtained using the T-TAS may 
reflect individual variability of thrombus formation. Within the PL chip, the rate of thrombus 
formation was shorter at higher shear rates which was reflected in all parameters measured 
(Figure 1B). This supports the evidence that high-shear rates favour the GPIb-IX-V/VWF 
axis to induce more efficient thrombus formation [19]. In contrast, the effect of  the shear rate 
within the AR chip was variable, in particular the onset (T10) (Figure 1D) where the value at 
the high shear was greater than at the low shear in contrast to previous findings [4, 6]. 
However, an increased rate of thrombus growth (T10-80) in accordance with an increase in 
shear rate was observed on AR chip similar to that on PL chip, indicating that the shear rates 
accelerated the growth rate of the thrombus. Shear rate enhancement of T-TAS parameters 
were also reported by Hosokawa et al., and Yamaguchi et al., [4, 6].  In our study, the T-TAS 
14 
 
also exhibited high intra-assay coefficients of variation (CV) within both chips (Table 1).  
Typical CVs obtained were much higher than those described by Yamaguchi et al. although 
their sample size (n=5) was smaller [4].  
We also evaluated the utility of T-TAS in detecting the effect of antithrombotic therapy on 
haemostasis using two types of drugs. 1) The antiplatelet drug Ticagrelor (P2Y12 antagonist) 
and 2) The anticoagulant Rivaroxaban (factor Xa inhibitor). Ticagrelor (10 µM) completely 
suppressed thrombus formation within the PL chip. These findings agree with Hokosawa et 
al. who also previously demonstrated that thrombus formation within the PL chip was 
inhibited by P2Y12 antagonists [5, 8]. In contrast, the inhibitory effect of Ticagrelor on 
thrombus formation was not observed within the AR chip. As thrombus formation within the 
AR at low shear rate is more dependent upon fibrin formation [6, 20], it is possible that P2Y12 
inhibitors are therefore expected to have no effect in this chip as platelets play little or no role 
in thrombus formation at low shear rates [7, 21]. Secondly, platelets within the AR chip could 
also be activated via the PAR-1 receptor by thrombin which is generated from activation of 
the coagulation pathways [21]. This was demonstrated by Hokosawa et al. by demonstrating 
that PAR-1 antagonism reduced thrombus formation within the AR chip [7]. In contrast, 
Rivaroxaban (1µM) incubation with whole blood within the AR chip displayed considerable 
variability on affecting thrombus formation with a delayed onset despite complete thrombus 
formation (figure 1G). Hokosawa et al. also demonstrated that Rivaroxaban (1µM) only 
moderately suppressed thrombus formation within the AR chip [9]. However, Sugihara et al. 
demonstrated that Rivaroxaban at the estimated clinical peak dose (800 nM) significantly 
suppressed thrombus formation [22]. Furthermore, Hosokawa et al., also used T-TAS to show 
that the anticoagulant effect of thrombus formation was intensified when anticoagulant and 
antiplatelet drugs were used in combination [9]. These findings suggest that T-TAS could be a 
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clinically useful tool for monitoring the antithrombotic effect on both platelet and coagulation 
pathways.  
 
Furthermore, we performed a comparative evaluation of the T-TAS using the PL chip with 
GAPP patients with suspected platelet function defects and compared the results with the 
gold standard of lumi-LTA. Comparison of the overall results in 30 patients with normal 
platelet counts (Table 2) demonstrated a good agreement between T-TAS (PL chip) and lumi-
LTA with concordance in 87% of samples tested. As 67% of samples were defined as normal 
by lumi-LTA, T-TAS therefore gave a NPV of 86% suggesting that the test could be a 
potential screening tool for the characterisation of platelet function disorders.  Interestingly, 
T-TAS also detected all patients with COX-like defects and secretion defects (Figure 2D). 
This finding is consistent with earlier reports showing that T-TAS was able to detect all 
patients diagnosed with SPD [12]. T-TAS also showed high consistency in detecting 
abnormalities in patients with multiple defects. This finding supports the earlier report 
suggesting that T-TAS is reliable in detecting more severe forms of platelet defects such 
Bernard-Soulier syndrome [12]. However, T-TAS failed to detect thrombus formation in all 
patients with thrombocytopenia including three patients that gave normal responses by lumi-
LTA (Figure 2A and 2B). This might suggest that T-TAS is not reliable for testing samples 
with low platelet counts and that thrombus formation is dependent on normal platelet 
numbers. An earlier study on healthy subjects demonstrated a good correlation between 
normal platelet counts and T-TAS parameters [4]. Further studies are required to investigate 
the relationship between platelet counts and T-TAS parameters. 
There is no single parameter that has been described to be more useful in defining 
haemostatic abnormalities within the T-TAS. Almost all studies evaluating bleeding disorders 
in the T-TAS have used AUC10/30 and to a lesser extent the T10 [11-13, 23].  AUC is 
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particularly useful in quantifying a decrease in thrombus formation when occlusion time is 
not achieved during the time period of assay. In our study almost all samples (7/8) with 
abnormalities detected by T-TAS exhibited low values of AUC10. One patient however, gave 
normal values of AUC10 but with delayed T10 parameters. Interestingly, the patient was also 
found to have a defect by lumi-LTA. This might therefore suggest that a combination of T10 
and AUC parameters are sufficient to identify any haemostatic abnormalities on T-TAS.   
The use of comparatively small blood volumes for T-TAS makes it practical for studying ex-
vivo thrombus formation in small animal models. This could potentially result in significant 
reduction of animal usage in research laboratories. To evaluate the utility of T-TAS for 
testing thrombus formation in mouse blood, we first analysed blood samples from WT mice. 
WT blood demonstrated more rapid total thrombus formation compared to human blood. 
Similar results were reported on studies of blood from miniature pigs [14], suggesting that 
these animals might exhibit increased thrombogenicity than humans, possibly due to higher 
platelet counts (Table 4). As expected, all KO models displayed poor thrombus formation 
within the PL chip concurring with previous in vivo and in vitro findings [24]. In contrast, full 
thrombus formation was observed within the AR chip with all KO indicating that the 
coagulation pathways are normal and that platelets probably have little significant 
contribution to thrombus formation using this system, at a shear rate of 240 s−1 [23]. 
Our present study has several limitations. Firstly, the study was performed with only a small 
group of patients suspected to have platelet function disorders. Therefore, for future studies it 
would be necessary to enrol a larger number of patients with known platelet function defects 
as well as other haemostatic abnormalities such as coagulation defects (e.g haemophilia and 
VWD). Secondly, the study of antithrombotic drugs was performed using a single 
concentration of either ticagrelor or rivaroxaban and were evaluated separately. It would be 
of interest in future studies to evaluate the T-TAS with a full range of antiplatelet drugs with 
17 
 
different molecular targets and at different concentrations as well as in the combination 
with anticoagulant drugs. Lastly, the mouse models were only studied within the AR chip 
and at low shear rates. It would be of interest to determine if higher shear rates would also 
have detected similar platelet defects in these mice.    
In summary, T-TAS has demonstrated a good agreement with Lumi-LTA suggesting that the 
technique could be applied to potentially screening patients with platelet function defects. 
Moreover, the device might be a useful tool in monitoring antithrombotic therapy. Finally, we 
demonstrated that the T-TAS could provide valuable assistance in rapidly studying samples 
from animal models with the potential of reducing animal usage in research laboratories.  
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Tables  
Table 1 Intra-assay coefficients of variation (CV) in PL and AR chips measurements in a 
single sample obtained from a healthy control (n=10). 
 
 
Table 2 Analysis of the agreement between the T-TAS and lumi-LTA in patient samples 
(n=30) displaying sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV).  
 
 
Table 3 T-TAS measurements in samples from WT mice (n=5) performed on both PL and 
AR chips using different shear rates. Data presented as mean and SD. 
 
Table 4 Measurement of whole blood platelet count and MPV in samples from WT mice 
(n=5) and human (n=22). Data presented as mean and SD. 
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Figure legends 
Figure 1. Measurements of blood from healthy controls (n=22) using the PL chip and AR 
chip. For panel A and C, flow pressure curves of all individuals measured at low shear rates 
on PL chip (1000 s− 1) and AR chip (240 s− 1), respectively. For panel B and D, distribution of 
the T-TAS measurements from different shear rates using PL chip and AR chip, respectively. 
For panel E and F, effects of the ticagrelor (10µM) on blood from healthy controls (n=4) 
measured on PL chip and AR chip, respectively. For panel G, effects of the rivaroxaban 
(1µM) on blood from healthy controls (n=5) measured on AR chip (bars represent median 
values). Statistical analysis performed by the Mann Whitney U test and the one-way ANOVA 
test with Sidak’s adjustment for multiple comparisons (***p <0.001, **p<0.01 and *p<0.05). 
Figure 2. Measurements of thrombus formation in the PL-chip (1000 s−1) with whole blood 
samples from healthy controls (n=22), patients (n=20) no detectable platelet defects by Lumi-
LTA, patients (n=10) with platelet defects as defined by lumi-LTA and patients (n=7) with 
thrombocytopenia. Panel A, flow pressure curves display control (black), normal T-TAS 
(green), abnormal T-TAS (red) and patients with thrombocytopenia (blue). Panel B, 
distribution of the T-TAS measurements display control (black circles), normal T-TAS (green 
circles), abnormal T-TAS (red circles) and patients with thrombocytopenia (blue circles). 
Panel C, summary of overall patients results (n=30) analysed on lumi-LTA and T-TAS 
comparing between normal (blue) and abnormal (red). Panel D, classification of platelet 
function defects among patients detected by lumi-LTA (blue) and T-TAS (red). The results 
were considered to be abnormal (by lumi-LTA) as previously established in the GAPP 
program using samples from healthy subjects (Dawood et al 2012) and (by T-TAS) when 
they fall below the cut-off values (5th percentile) calculated from healthy individuals. 
Statistical analysis performed by the Mann Whitney U test (bars represent the median 
values). Significance as compared to control in each parameter (***p<0.001 and *p<0.05). 
Figure 3. Measurements of thrombus formation within the PL-chip (1000 s−1) and AR-chip 
(240 s−1) with blood from human (black) and WT mice (red). Panel A, flow pressure curves 
observed within PL-chip (1000 s−1). Panel B, distribution of the T-TAS measurements 
obtained from PL-chip (1000 s−1). Panel C, flow pressure curves observed within AR-chip 
(240 s−1). Panel D, distribution of the T-TAS measurements obtained from AR-chip (240 
s−1). Statistical analysis performed by the Mann Whitney U test (bars represent median 
values). Significance as compared between human and WT blood in each parameter 
(***p<0.001). 
 
 
 
